Baillie Gifford & Co. Sells 375,812 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Baillie Gifford & Co. reduced its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 1.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 24,864,058 shares of the company's stock after selling 375,812 shares during the quarter. Baillie Gifford & Co. owned about 6.36% of Recursion Pharmaceuticals worth $168,081,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Allspring Global Investments Holdings LLC acquired a new position in shares of Recursion Pharmaceuticals during the 3rd quarter worth about $25,000. Decker Retirement Planning Inc. acquired a new position in shares of Recursion Pharmaceuticals during the 4th quarter worth about $26,000. GAMMA Investing LLC grew its position in shares of Recursion Pharmaceuticals by 1,979.2% in the 4th quarter. GAMMA Investing LLC now owns 5,198 shares of the company's stock valued at $35,000 after purchasing an additional 4,948 shares during the period. Farther Finance Advisors LLC grew its position in shares of Recursion Pharmaceuticals by 176.9% in the 3rd quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company's stock valued at $42,000 after purchasing an additional 4,091 shares during the period. Finally, KBC Group NV grew its position in shares of Recursion Pharmaceuticals by 79.9% in the 3rd quarter. KBC Group NV now owns 7,602 shares of the company's stock valued at $50,000 after purchasing an additional 3,377 shares during the period. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Stock Down 4.8 %

NASDAQ:RXRX traded down $0.52 during trading hours on Thursday, reaching $10.35. 38,491,264 shares of the stock were exchanged, compared to its average volume of 25,721,521. Recursion Pharmaceuticals, Inc. has a twelve month low of $5.60 and a twelve month high of $15.74. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. The firm has a 50 day moving average of $7.45 and a 200 day moving average of $6.98. The stock has a market cap of $4.04 billion, a PE ratio of -6.76 and a beta of 0.86.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. KeyCorp decreased their price objective on Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating for the company in a research report on Wednesday, January 8th. Needham & Company LLC reiterated a "buy" rating and issued a $11.00 price objective on shares of Recursion Pharmaceuticals in a research report on Thursday, February 6th.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.